反応式
[N:1]1[CH:6]=[CH:5][C:4]([C:7]2[NH:11][C:10]3[CH:12]=[CH:13][CH:14]=[C:15]([C:16]([OH:18])=O)[C:9]=3[N:8]=2)=[CH:3][CH:2]=1.[B-](F)(F)(F)F.C[CH2:25][O:26][C:27]([C:29]([C:39]#N)=[N:30]OC(N(C)C)=[N+](C)C)=[O:28].[CH:41](N(C(C)C)CC)([CH3:43])[CH3:42]>CN(C=O)C>[CH3:25][O:26][C:27](=[O:28])[C@H:29]([CH2:39][CH:41]([CH3:43])[CH3:42])[NH:30][C:16]([C:15]1[C:9]2[N:8]=[C:7]([C:4]3[CH:3]=[CH:2][N:1]=[CH:6][CH:5]=3)[NH:11][C:10]=2[CH:12]=[CH:13][CH:14]=1)=[O:18]参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
120 mg (0.5 mmol) of 2-(pyrid-4-yl)-1H-benzimidazole-4-carboxylic acid (1d) and 84 mg (0.5 mmol) of H-(L)-leucine methyl ester were dissolved in 5 ml of DMF. 164 mg (0.5 mmol) of TOTU and 0.086 ml of diisopropylethylamine were added and the mixture was stirred at RT for 3 h. The precipitate was filtered off and the filtrate was concentrated. The residue was dissolved in ethyl acetate, the solution was washed with water, and the organic phase was dried using anhydrous sodium sulfate and concentrated. Yield: 180 mg (98%).
後処理
- filtrationThe precipitate was filtered off
- concentrationthe filtrate was concentrated
- dissolutionThe residue was dissolved in ethyl acetate
- washthe solution was washed with water
- customthe organic phase was dried
- concentrationconcentrated
出典と根拠
- ORDレコード
- ord-184fe2b0b5f24a8d8c53a2db5518b886
- 出典データセット
- uspto-grants-2002_03
- 特許番号
- US06358978B1
関連ノート
読み込み中…